<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194842</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1333-GUCG</org_study_id>
    <secondary_id>2014-001787-36</secondary_id>
    <nct_id>NCT02194842</nct_id>
  </id_info>
  <brief_title>Phase III Radium 223 mCRPC-PEACE III</brief_title>
  <acronym>PEACE III</acronym>
  <official_title>A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academic and Community Cancer Research United</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Trials Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Urologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this randomized phase III open label trial is to assess if upfront
      combination of enzalutamide and Ra223 improves radiological progression-free survival
      compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration
      resistant prostate cancer patients metastatic to bone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>radiological progression-free survival</measure>
    <time_frame>46 months after first patient entry</time_frame>
    <description>Radiological progression free survival (rPFS1) is defined according to the recommendations of the &quot;Prostate-Cancer clinical trials Working Group&quot; version 2 and referred to as the &quot;PCWG2&quot;; for the setting &quot;delay/prevent&quot; progression.
An event of progression according to their definition is either of:
Objective progression of the disease according to RECIST criteria for soft tissue lesions with the additional requirement that progression at the first follow-up assessment be confirmed by a second scan ≥ 6 weeks apart
Appearance of ≥ 2 new bone lesions (see chapter 6 for clinical examinations required) and for the first follow-up assessment only, a confirmatory scan performed ≥ 6 weeks later that shows a minimum of two or more additional new lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>63 months after first patient entry</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate cancer specific survival</measure>
    <time_frame>63 months after first patient entry</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First symptomatic skeletal event</measure>
    <time_frame>46 and 63 months after first patient entry</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time and incidence of first skeletal progression-free</measure>
    <time_frame>46 and 63 months after first patient entry</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from entry to initiation of next systemic therapy</measure>
    <time_frame>46 and 63 months after first patient entry</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatments elected after first disease progression</measure>
    <time_frame>46 and 63 months after first patient entry</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second progression-free survival in sequential regimen</measure>
    <time_frame>46 and 63 months after first patient entry</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>46 and 63 months after first patient entry</time_frame>
    <description>Brief Pain Inventory questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression</measure>
    <time_frame>63 months after first patient entry</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of adverse events</measure>
    <time_frame>63 months after first patient entry</time_frame>
    <description>Adverse events will be graded according to the &quot;Common Terminology Criteria for Adverse events&quot; CTCAE, version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to use of opioid analgesics</measure>
    <time_frame>63 months after first patient entry</time_frame>
    <description>number of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>46 and 63 months after first patient entry</time_frame>
    <description>EQ5D-5L questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enzalutamide will be given at a dose of 160 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide and Ra223</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ra223 will be administered 50kBq/kg standard dose monthly for 6 months and given in combination with enzalutamide at a dose of 160 mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ra223</intervention_name>
    <arm_group_label>Enzalutamide and Ra223</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_label>Enzalutamide and Ra223</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of prostate adenocarcinoma:

               1. Asymptomatic or mildly symptomatic (defined as no opioids and Brief Pain
                  Inventory score)

               2. Metastatic to bone with ≥ 2 bone metastases (area of increase uptake on 99mTC BS
                  (Technetium-99m bone scintigraphy) confirmed by standard X-Ray, Computed
                  tomography (CT), or Magnetic resonance imaging (MRI)) with or without additional
                  lymph node metastases. Visceral metastases are not allowed

               3. Progressive Castration-resistant prostate cancer (CRPC) according to Prostate
                  Cancer Working Group 2 (PCWG2) i.e. either of:

          -  For patients who manifest disease progression solely as a rising Prostate-specific
             antigen (PSA) level. PCWG2 criteria require documentation of a sequence of rising PSA
             values at a minimum of 1-week intervals with the last value ≥ 2 ng/ml.

          -  For patients with disease progression manifest in the bone, irrespective of
             progression by rising PSA, PCWG2 guidelines require appearance of 2 or more new
             lesions. Ambiguous results should be confirmed by other imaging modalities than bone
             scan and x-ray (e.g.: CT-scan or MRI).

          -  For patients with disease progression manifest at nodal sites, irrespective of
             progression by rising PSA, PCWG2 requires progression according to RECIST 1.1.

          -  Ongoing androgen deprivation therapy with LHRH (Human luteinizing hormone-releasing
             hormone) agonist or antagonist or bilateral orchiectomy

          -  Patients must be at least 18 years old

          -  WHO Performance status 0-1

          -  Charlson score ≤ 3

          -  Castrate serum levels of testosterone (&lt; 50 ng/dL)

          -  Biochemistry and hematology:

               1. Adequate bone marrow function (absolute neutrophil count 1.5109/L; platelets 100
                  109/L, and hemoglobin &gt; or = 10.0 g/dl.).

               2. Total bilirubin level ≤ 1.5 x institutional upper limit of normal (ULN), except
                  for patient with Gilbert's disease 5.0 ULN

               3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; or = 2.5 x
                  ULN

               4. Creatinine &lt; or= 1.5 x ULN

               5. Albumin &gt; 25 g/L

          -  Normal cardiac function according to local standard by 12-lead Electrocardiogram (ECG)
             (complete, standardized 12-lead recording)

          -  Able to swallow the study drug and comply with study requirements

          -  Prior or concomitant therapy

               1. Prior docetaxel is permitted under the following conditions: start within 2
                  months of Androgen deprivation therapy (ADT) initiation, given for a maximum of 6
                  cycles and progression within 6 months of the last dose of docetaxel.

               2. Previous treatment with bicalutamide, flutamide, prednisone, or dexamethasone is
                  allowed if it was stopped at least 4 weeks prior to entry in the study

               3. Patients taking bisphosphonates or denosumab are eligible if they have received a
                  stable dose for 4 weeks or more prior to randomization. (These treatments may
                  then be continued on study)

          -  use of adequate birth control measures during the study treatment period and for at
             least 3 months after last dose of enzalutamide and 6 months after the last dose of
             Ra223.

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial

          -  Before patient randomization, written informed consent must be given according to
             ICH/GCP, and national/local regulations

        Exclusion Criteria:

          -  No known history of central nervous system metastases or leptomeningeal tumor spread.

          -  No significant cardiovascular disease including:

               1. Myocardial infarction within 6 months prior to screening

               2. Uncontrolled angina within 3 months prior to screening

               3. Congestive heart failure New York Heart Association (NYHA) class III or IV, or
                  patients with history of congestive heart failure NYHA class III or IV in the
                  past, unless a screening echocardiogram or multi-gated acquisition scan (MUGA)
                  performed within 3 months results in a left ventricular ejection fraction that is
                  ≥ 45%

               4. History of clinically significant ventricular arrhythmias (e.g., ventricular
                  tachycardia, ventricular fibrillation, torsades de pointes)

               5. History of Mobitz II second degree or third degree heart block without a
                  permanent pacemaker in place

               6. Uncontrolled hypertension as indicated by a resting systolic blood pressure &gt; 170
                  mm Hg or diastolic blood pressure &gt; 105 mm Hg at screening

               7. Hypotension as indicated by systolic blood pressure &lt; 86 millimeters of mercury
                  (mm Hg) at screening

               8. Bradycardia as indicated by a heart rate of &lt; 45 beats per minute on the
                  screening ECG and on physical examination

          -  patients having received docetaxel for CRPC are excluded.

          -  No prior treatment with enzalutamide or Ra223

          -  No prior and concomitant treatment with Cyp17 inhibitors (abiraterone, orteronel) and
             ketoconazole

          -  No prior hemibody external radiotherapy. Patients who received other types of prior
             external radiotherapy are allowed provided that the bone marrow function is assessed
             and meets the protocol requirements for hemoglobin, absolute neutrophil count and
             platelets

          -  No prior therapy with other radionuclides (e.g., strontium-89, samarium-153,
             rhenium-186, or rhenium-188)

          -  No involvement in another therapeutic trial involving an experimental drug

          -  No anticancer therapy or treatment with another investigational agent within the last
             4 weeks prior to randomization

          -  No known hypersensitivity to compounds related to enzalutamide or Ra223

          -  No prior history of malignancies other than prostate adenocarcinoma (except patients
             with basal cell, squamous cell carcinoma of the skin, in-situ carcinoma or low-grade
             superficial bladder cancer), or the patient has been free of malignancy for a period
             of 3 years prior to randomization date

          -  No history of seizure, including any febrile seizure, loss of consciousness, or
             transient ischemic attack within 12 months of enrollment (registration date), or any
             condition that may pre-dispose to seizure (e.g., prior stroke, brain arterio-venous
             malformation, head trauma with loss of consciousness requiring hospitalization)

          -  No major surgery within 4 weeks prior to treatment

          -  No intake of narcotic analgesia for bone pain

          -  No drug or alcohol abuse

          -  No other serious illness or medical condition, such as but not limited to:

               1. Any infection ≥ Grade 2 according to National Cancer Institute Common Terminology
                  Criteria for Adverse Events (NCI-CTCAE) version 4

               2. No gastrointestinal disorder affecting absorption (e.g., gastrectomy or active
                  peptic ulcer disease)

               3. Crohn's disease or ulcerative colitis

               4. Bone marrow dysplasia

               5. Fecal incontinence

               6. Life-threatening illness unrelated to cancer

          -  No condition which, in the investigator's opinion, makes the patient unsuitable for
             trial participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Tombal, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Cliniques Universitaires de Saint Luc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silke Gillessen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evelien Nollet, PhD</last_name>
    <phone>+3227741571</phone>
    <email>1333@eortc.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EORTC</last_name>
    <phone>+3227741611</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Universitaire Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie Hambye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Roumeguere</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand Tombal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Van Den Brande</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignace Billiet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur - Site Sainte-Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Palumbo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gino Pelgrims</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dinant Godinne - UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel D'Hondt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gedske Daugaard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut J. Paoli &amp; I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenelle Gravis, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Deshayes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yohann Loriot, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Adelaide and Meath Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ray McDermott, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale B.Ramazzini</name>
      <address>
        <city>Carpi</city>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Mucciarini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ugo De Giorgi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nole Franco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University Of Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <zip>80211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elzbieta Senkus-Koneftka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwona Lugowska</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejo Rodriguez-Vida</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital De La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Maroto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Doctor Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara Pedro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gallardo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Gomez Veiga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Spahn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St Gallen</name>
      <address>
        <city>St Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Gillessen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hermanns, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ananya Choudhury</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust - City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sundar Santhanam</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

